超越转基因小鼠:阿尔茨海默氏症疾病的新兴模型和翻译策略
Paula Alexandra Lopes1,2, José L Guil-Guerrero3
1CIISA-Centro de Investigação Interdisciplinar em Sanidade Animal, Faculdade de Medicina Veterinária, Universidade de Lisboa, 1300-477 Lisboa, Portugal.
International journal of molecular sciences
|June 26, 2025
概括
开发更好的阿尔茨海默病 (AD) 模型对于找到有效的治疗方法至关重要. 本综述将传统的小鼠模型与较新的替代方案进行比较,主张采取综合方法来加速阿尔茨海默病的治疗发现.
科学领域:
- 神经科学是一个神经科学.
- 遗传学 是一个遗传学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 阿尔茨海默氏症 (AD) 是痴呆的主要原因,可用的疾病修饰治疗有限.
- 目前的实验模型,特别是传统的转基因小鼠,往往无法完全复制零星,晚期发作的AD的复杂性.
- 这种翻译相关性的差距阻碍了有效疗法的发现.
研究的目的:
- 批判性地评估和比较现有的老鼠和替代模型用于阿尔茨海默病 (AD) 研究.
- 确定强项,局限性和未来发展方向,以开发更可翻译的AD模型.
- 为了指导AD的增强治疗发现和临床翻译.
主要方法:
- 对传统的转基因小鼠模型和替代性AD模型 (斑马鱼,多索菲拉,C. elegans,非人类灵长类动物,人类大脑器官) 的全面审查和比较分析.
- 讨论新兴创新,包括基因工程,神经成像,计算建模和药物重新用途.
- 考虑道德上的影响和公平获得诊断和治疗.
主要成果:
- 传统的小鼠模型提供了对粉样β和病理的洞察力,但缺乏零星,晚期发作的AD的复杂性.
- 替代模型提供了互补的见解和多样化的实验优势,显示了更广泛的AD研究的希望.
- 技术创新和多模型方法对于提高预测能力和加速临床翻译至关重要.
结论:
- 建议采用综合多种方法的多模型,多学科战略,以增强AD研究的预测能力.
- 开发更准确,更有效,更与人类相关的模型对于对抗阿尔茨海默病至关重要.
- 强调伦理考虑和公平获取对于推动AD诊断和治疗是必要的.
相关概念视频
Alzheimer's Disease: Overview
684
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
684
Alzheimer's Disease: Treatment
265
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
265


